Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Bevacizumab Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer

August 2nd 2011

Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.

Judge Rules BRCA Genes Can Be Patented, Overturning Previous Decision

August 1st 2011

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin

August 1st 2011

A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.

Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer

July 27th 2011

Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.

Dr. Vogelzang Discusses the Cabozantinib Trial Design

July 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Studies Find That Talc-Based Powder Increases the Risk of Ovarian Cancer

June 17th 2011

Long-term use of talc-based powder significantly increased the risk of invasive ovarian cancer in a large case-control study

Diagnosing Ovarian Cancer: Does it matter when

June 10th 2011

More often than not, ovarian cancer is diagnosed at an advanced stage

NCCN's 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 24th 2011

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Towards Personalized Medicine in Ovarian Cancer

May 19th 2011

The goal of personalized medicine remains in its infancy as oncologists strive to determine treatments specific to a patient's tumor characteristics

Study Results Show Ovarian Cancer Deaths Are Not Reduced by Early-Detection Screening Methods

May 18th 2011

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Dr. Markman Discusses the Olaparib Phase II Trial

May 18th 2011

Dr. Markman Discusses the Olaparib Phase II Trial

Dr. Pecora on Ovarian Cancer PARP Inhibitor

May 18th 2011

Dr. Pecora on Ovarian Cancer PARP Inhibitor for Ovarian Cancer

Intraperitoneal Struggles in Ovarian Cancer Treatments

May 9th 2011

Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments

Dr. Karlan Discusses AMG 386 in Recurrent Ovarian Cancer

May 5th 2011

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Dr. Karlan Describes AMG 386 Side Effects

April 29th 2011

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

MicroRNA May Predict Response to Bevacizumab

April 28th 2011

The results of a small clinical trial showed that low-level expression of a microRNA correlated with improved progression-free survival

FDA Grants NKTR-102 Orphan Drug Status for Treatment of Ovarian Cancer

April 26th 2011

Nektar Therapeutics announced that its oncology drug candidate, NKTR-102, has been granted orphan drug status